FCM
GBT
Farallon Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-450,000
| Closed | -$30.6M | – | 317 |
|
|
2022
Q3 | $30.6M | Buy |
+450,000
| New | +$30.6M | 0.17% | 85 |
|
|
2022
Q2 | – | Sell |
-169,458
| Closed | -$5.87M | – | 329 |
|
|
2022
Q1 | $5.87M | Buy |
169,458
+83,004
| +96% | +$2.88M | 0.03% | 176 |
|
|
2021
Q4 | $2.53M | Buy |
+86,454
| New | +$2.53M | 0.01% | 203 |
|
|
2020
Q4 | – | Sell |
-600,000
| Closed | -$33.1M | – | 156 |
|
|
2020
Q3 | $33.1M | Buy |
+600,000
| New | +$33.1M | 0.23% | 74 |
|
|
2020
Q1 | – | Sell |
-750,000
| Closed | -$59.6M | – | 119 |
|
|
2019
Q4 | $59.6M | Sell |
750,000
-862,069
| -53% | -$68.5M | 0.4% | 46 |
|
|
2019
Q3 | $78.2M | Buy |
1,612,069
+487,069
| +43% | +$23.6M | 0.59% | 38 |
|
|
2019
Q2 | $59.2M | Sell |
1,125,000
-375,000
| -25% | -$19.7M | 0.38% | 52 |
|
|
2019
Q1 | $79.4M | Buy |
1,500,000
+50,000
| +3% | +$2.65M | 0.6% | 41 |
|
|
2018
Q4 | $59.5M | Buy |
1,450,000
+80,000
| +6% | +$3.28M | 0.44% | 41 |
|
|
2018
Q3 | $52.1M | Buy |
1,370,000
+185,000
| +16% | +$7.03M | 0.31% | 49 |
|
|
2018
Q2 | $53.6M | Buy |
+1,185,000
| New | +$53.6M | 0.33% | 49 |
|
|
2018
Q1 | – | Sell |
-340,000
| Closed | -$13.4M | – | 101 |
|
|
2017
Q4 | $13.4M | Buy |
+340,000
| New | +$13.4M | 0.11% | 60 |
|